Mazdutide Latest Research: New Indications, Trials & What’s Coming

Introduction

Mazdutide has the most active research pipeline of any drug in the GLP-1/glucagon dual agonist class. After NMPA approval in China in June 2025 for obesity and the parallel approval pathway for type 2 diabetes, Innovent and Eli Lilly are running multiple phase 3 trials targeting additional indications including MASH, obstructive sleep apnea, heart failure with preserved ejection fraction, and chronic kidney disease.

The science is interesting because the glucagon receptor component does things GLP-1 alone can’t. Glucagon raises energy expenditure, mobilizes liver fat, and may have direct effects on cardiac and renal function. Whether these translate into approved indications depends on phase 3 outcomes still to come, but early data is promising in several areas.

This article covers the current state of mazdutide research as of 2026, the indications being pursued, the major trials running or recently completed, and what the data suggests about where this drug fits compared to other GLP-1 family members.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is the Current Approval Status of Mazdutide?

Mazdutide has full marketing approval in China from the NMPA, granted in June 2025 for chronic weight management in adults with obesity (BMI ≥28) or overweight (BMI ≥24) with comorbidities. The diabetes indication was approved separately, supported by the DREAMS phase 3 trials.

Quick Answer: GLORY-1 (Ji et al. 2025 NEJM) supported June 2025 China approval for obesity

In the United States, mazdutide has no FDA approval. Eli Lilly holds global rights outside Greater China and is running phase 3 trials to support a future US filing. No firm timeline has been disclosed, but typical phase 3 to approval timelines suggest 2027 or later for US availability.

The European Medicines Agency has not received a marketing authorization application. Japan and other Asian markets are also potential future markets.

What Did the GLORY-1 Phase 3 Trial Show?

GLORY-1, published by Ji and colleagues in NEJM in 2025, is the key phase 3 trial for mazdutide in obesity. The trial enrolled 610 Chinese adults with overweight or obesity and ran for 48 weeks.

Primary endpoint: mean percent change in body weight from baseline. At the 6 mg dose, weight loss averaged 14.4% (in the analysis of all randomized participants) and around 18% in completers who reached the maintenance dose. The 4 mg dose produced approximately 12.5% weight loss. Placebo participants lost about 0.3%.

Secondary endpoints all moved in favorable directions. Mean waist circumference dropped 12 cm at the 6 mg dose. Systolic blood pressure fell 6 to 7 mmHg. Triglycerides dropped 25%. HbA1c (in participants without diabetes) showed small but meaningful improvements. The most common adverse events were nausea (30%), diarrhea (12%), and vomiting (10%).

GLORY-2 is an ongoing follow-up trial in Chinese adults with obesity plus weight-related comorbidities, expanding the evidence base for the obesity indication.

What Did the DREAMS Trials Show for Diabetes?

DREAMS-1 enrolled adults with type 2 diabetes inadequately controlled on lifestyle alone. At 24 weeks, HbA1c dropped 1.6 percentage points at the 4 mg dose versus 0.1 in placebo. Mean weight loss was about 6.7% in that arm.

DREAMS-2 added mazdutide to metformin in patients with inadequate control on metformin alone. The trial showed mazdutide added significant glycemic improvement and weight loss on top of metformin. HbA1c reductions of 1.4 to 1.8 percentage points were observed at the higher dose tiers. Hypoglycemia rates were low and similar to placebo when mazdutide was used without insulin or sulfonylureas.

The DREAMS data supported the type 2 diabetes indication and informed dosing for diabetic patients. The 4 mg and 6 mg doses are both options for diabetes depending on weight loss goals and tolerance.

What’s Happening with Mazdutide for MASH?

A phase 2 trial of mazdutide in adults with metabolic dysfunction-associated steatohepatitis (MASH) reported results showing 60 to 70% reduction in liver fat content (measured by MRI proton density fat fraction) over 24 weeks at higher doses. This is a substantial drop, comparable to or better than what semaglutide achieved in the ESSENCE trial.

The dual mechanism is particularly attractive for MASH. Glucagon receptor activation directly increases liver fat oxidation and reduces de novo lipogenesis. GLP-1 reduces weight, which is the most evidence-based intervention for MASH improvement. Together, the two mechanisms attack the disease from both directions.

A phase 3 MASH trial is in planning or early enrollment. If successful, mazdutide could become a key therapy for MASH alongside resmetirom (MAESTRO-NASH, NEJM 2024), with the added benefit of weight loss that resmetirom doesn’t provide. Whether MASH approval will be sought first in China, US, or both isn’t yet clear.

Is Mazdutide Being Studied for Sleep Apnea?

Obstructive sleep apnea is a likely additional indication for mazdutide given its strong weight loss effect and the precedent set by tirzepatide. The SURMOUNT-OSA trial led to FDA approval of tirzepatide for OSA in December 2024.

Mazdutide hasn’t yet had a dedicated phase 3 OSA trial reported, but the trial program is reportedly expanding to include sleep apnea endpoints. The biological rationale is strong: weight loss reduces upper airway fat deposition, which is the primary mechanism behind obesity-related OSA.

Patients with both obesity and OSA may benefit from mazdutide for the weight loss alone, with secondary improvement in sleep apnea severity. The Apnea-Hypopnea Index (AHI) typically drops by 25 to 50% with substantial weight loss in OSA patients.

What About Heart Failure and Cardiovascular Outcomes?

A dedicated cardiovascular outcomes trial for mazdutide is in planning. Trial data from GLORY-1 and DREAMS already shows favorable changes in cardiovascular surrogates: blood pressure down 6 to 7 mmHg, triglycerides down 25%, modest LDL improvement, and reduced inflammatory markers.

These surrogates predict cardiovascular benefit based on what SELECT (Lincoff et al. 2023 NEJM) showed for semaglutide: a 20% reduction in major adverse cardiac events at 39.8 months. Whether mazdutide replicates this in a dedicated CV outcomes trial is the question for the next several years.

Heart failure with preserved ejection fraction (HFpEF) is a specific area of interest. STEP-HFpEF showed semaglutide significantly improved exercise capacity and quality of life in HFpEF patients with obesity. A mazdutide HFpEF trial would test whether the dual mechanism provides additional benefit, particularly through increased energy expenditure and reduced cardiac fat.

What About Kidney Disease?

Chronic kidney disease (CKD) outcomes in type 2 diabetes have become a major GLP-1 research area following FLOW (Perkovic et al. 2024 NEJM), which showed semaglutide reduced kidney and CV death by 24% in CKD patients with T2D. Mazdutide trials in CKD are reportedly being designed.

The mechanism for kidney protection from GLP-1 drugs isn’t fully understood. Hypotheses include direct effects on glomerular hemodynamics, reduced inflammation, and indirect benefits from blood pressure and glucose control. The glucagon receptor component of mazdutide adds an additional unknown: glucagon’s net effect on kidney function isn’t well characterized.

Without specific CKD trial data, mazdutide is being prescribed in China for patients with stable kidney function (eGFR above 30). Severe kidney impairment trials would be a longer-term project.

Key Takeaway: Phase 2 MASH data shows roughly 60 to 70% reduction in liver fat content at high doses

How Does Mazdutide Compare to Retatrutide?

Retatrutide is Eli Lilly’s investigational triple agonist hitting GLP-1, GIP, and glucagon receptors. Phase 2 data showed approximately 24% weight loss at 48 weeks at the highest dose, which is the strongest reported weight loss for any drug in this class.

Mazdutide produces about 18% at 48 weeks in GLORY-1. The triple mechanism of retatrutide may explain the additional weight loss, with each receptor contributing complementary effects. Retatrutide phase 3 data is expected 2026 to 2027.

The clinical positioning of these drugs will depend on long-term safety data, side effect profiles, cost, and access. Mazdutide has a head start with current approval in China; retatrutide may have stronger weight loss if phase 3 confirms phase 2 results. The two could end up as complementary options rather than direct competitors.

What About Combination Therapies?

Mazdutide as part of combination therapy is being explored. Combinations with SGLT2 inhibitors, with metformin (already supported by DREAMS-2), and possibly with newer agents like bimagrumab (a muscle-sparing agent for body composition) are areas of research interest.

The rationale for combination therapy is targeting multiple mechanisms simultaneously. A patient on mazdutide plus an SGLT2 inhibitor gets weight loss from appetite suppression and energy expenditure (mazdutide) plus glucose excretion and cardio-renal benefits (SGLT2). Both classes show CV outcomes benefit independently.

Long-term safety and efficacy of these combinations remains to be established in dedicated trials.

What Does the FDA Approval Timeline Look Like?

Realistically, mazdutide US approval is in the 2027 to 2028 window if Eli Lilly’s global phase 3 trials succeed. Standard FDA review of new molecular entities is 10 to 12 months after filing, with priority review options shortening this further.

Lilly hasn’t publicly confirmed a US filing timeline. Their portfolio decisions depend on retatrutide’s outcomes as well; if retatrutide produces clearly superior weight loss, Lilly may prioritize that drug for the US market. If retatrutide has safety issues, mazdutide may move up.

Patients waiting for mazdutide in the US should know that semaglutide and tirzepatide (and compounded versions of both) remain effective options today. The free assessment quiz at TrimRx evaluates eligibility for these currently available treatments while research on mazdutide and other future options continues.

What About Long-term Safety Data?

Long-term mazdutide safety data extends to about 2 years of continuous use through trial follow-up. Class-wide GLP-1 safety data extends much further, with semaglutide having years of post-marketing surveillance.

The major safety questions for mazdutide that need more time to resolve include cancer risk (especially medullary thyroid cancer, a class-wide concern), long-term cardiovascular safety beyond surrogate markers, pancreatitis frequency in real-world use, and potential effects on bone density and lean mass with extended treatment.

Postmarketing surveillance in China through 2025 to 2030 will provide much of this data. Real-world studies typically catch rare adverse events that trials miss due to smaller sample sizes.

What’s the Role of Mazdutide Compared to GLP-1 Monotherapy?

The clinical positioning depends on what indication is being treated. For obesity alone, mazdutide produces similar or somewhat more weight loss than semaglutide and slightly less than tirzepatide based on trial-to-trial comparison. For MASH, the glucagon mechanism may provide unique benefit.

For diabetes, mazdutide is competitive with semaglutide and tirzepatide. The HbA1c reductions are in the same range. Weight loss as a secondary benefit is in the same range.

The dual receptor mechanism (versus single GLP-1) may be particularly useful in specific populations: patients with significant hepatic steatosis, patients who didn’t respond well to GLP-1 monotherapy, or patients with metabolic syndrome features that respond to glucagon receptor activation.

Bottom line: Retatrutide (triple agonist) phase 3 results, expected 2026 to 2027, will shape how mazdutide is positioned globally

FAQ

When Will Mazdutide Be Available in the US?

Earliest realistic availability is 2027 or 2028. Eli Lilly’s global phase 3 trials need to read out and the FDA review takes 10 to 12 months after filing.

Will Mazdutide Be FDA Approved for Diabetes First or Obesity First?

Either is possible. The trial program supports both indications. Lilly may pursue them simultaneously or sequentially depending on regulatory strategy.

Is Mazdutide Going to Be Available in Europe?

Likely yes, eventually. The EMA hasn’t received an application yet, but if the global phase 3 program succeeds, European launch is plausible 2027 to 2028.

What’s the Difference Between Mazdutide and Retatrutide?

Mazdutide is GLP-1 plus glucagon (dual). Retatrutide is GLP-1 plus GIP plus glucagon (triple). Retatrutide showed stronger weight loss in phase 2 but is still in development.

Will Mazdutide Be Approved for Adolescents?

No adolescent trials have been reported. Pediatric approval would require dedicated trials and is at least 5 to 7 years away if pursued.

How Does Mazdutide Affect Cancer Risk?

The class carries a theoretical concern about medullary thyroid cancer based on rodent data. Human surveillance data so far hasn’t shown a clear cancer signal. Long-term studies continue.

Is There a Generic Version Coming?

Mazdutide is a peptide that can’t be exactly genericized. Biosimilars are possible in the long term but typically reduce price by 15 to 30%, not 70 to 80% like small molecule generics.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.